A dual-response ratiometric fluorescent sensor for oxytetracycline determination in milk and mutton samples.

Owing to the adverse effects of oxytetracycline (OTC) residues on human health, it is of great importance to construct a rapid and effective strategy for OTC detection. Herein, we developed a dual-response fluorescence sensing platform based on molybdenum sulfide quantum dots (MoS2 QDs) and europium ions (Eu3+) for ratiometric detection of OTC. The MoS2 QDs, synthesized through an uncomplicated one-step hydrothermal approach, upon OTC integration into the MoS2 QDs/Eu3+ sensing system, exhibit a significant quenching of blue fluorescence due to the inner filter effect (IFE), simultaneously enhancing the distinct red emission of Eu3+ at 624 nm, a phenomenon attributed to the antenna effect (AE). This sensor demonstrates exceptional selectivity and sensitivity towards OTC, characterized by a linear detection range of 0.2-10 µM and a notably low detection limit of 2.21 nM. Furthermore, we achieved a visual semi-quantitative assessment of OTC through the discernible fluorescence color transition from blue to red under a 365 nm ultraviolet lamp. The practical applicability of this sensor was validated through the successful detection of OTC in milk and mutton samples, underscoring its potential as a robust tool for OTC monitoring in foodstuffs to safeguard food safety.

LPCAT2 inhibits colorectal cancer progression via the PRMT1/SLC7A11 axis.

Colorectal cancer (CRC) has a high degree of heterogeneity and identifying the genetic information of individual tumor cells could help enhance our understanding of tumor biology and uncover potential therapeutic targets for CRC. In this study, we identified LPCAT2+ tumor cell populations with less malignancy than LPCAT2- tumor cells in human and mouse CRC tissues using scRNA-seq. Combining in vitro and in vivo experiments, we found that LPCAT2 could inhibit the proliferation of CRC cells by inducing ferroptosis. Mechanistically, LPCAT2 arrested PRMT1 in cytoplasm of CRC cells via regulating acetylation of PRMT1 at the K145 site. In turn, PRMT1 enhanced SLC7A11 promoter activity. Thus, LPCAT2 attenuated the positive regulatory effect of PRMT1 on SLC7A11 promoter. Notably, SLC7A11 acts as a ferroptosis regulator. Furthermore, in LPCAT2 knockout mice (LPCAT2-/-) colon cancer model, we found that LPCAT2-/- mice exhibited more severe lesions, while PRMT1 or SLC7A11 inhibitors delayed the progression. Altogether, we elucidated that LPCAT2 suppresses SLC7A11 expression by inhibiting PRMT1 nuclear translocation, thereby inducing ferroptosis in CRC cells. Moreover, inhibitors of the PRMT1/SLC7A11 axis could delay tumor progression in CRC with low LPCAT2 expression, making it a potentially effective treatment for CRC.